Market Place
Sourcing Support
Anixa Biosciences Joins Redchip`s Biotech Resurgence Conference
09 Apr 2026 //
PR NEWSWIRE
Anixa Biosciences Joins Water Tower Research Insights Conference
07 Apr 2026 //
PR NEWSWIRE
Anixa Advances Breast Cancer Vaccine to Phase 2 After Ph1
01 Apr 2026 //
PR NEWSWIRE
Anixa Biosciences Presents Ovarian Cancer CAR-T Clinical Trial
30 Mar 2026 //
PR NEWSWIRE
Anixa Biosciences Granted Korean (MOIP) Patent For Breast Cancer
09 Mar 2026 //
PR NEWSWIRE
Anixa Biosciences Hosts 2026 Annual Meeting, Shares Update
02 Mar 2026 //
PR NEWSWIRE
Anixa Bio To Keynote Sc Clinical & Translational Research
23 Feb 2026 //
PR NEWSWIRE
Anixa Bio Sees Positive Ovarian Cancer CAR-T Trial Results;
09 Feb 2026 //
PR NEWSWIRE BIO
Anixa Biosciences Gets USAN Council Approval For CAR-T Therapy
02 Feb 2026 //
PR NEWSWIRE
Anixa Biosciences Granted Patent By (IMPI) For Breast Cancer
27 Jan 2026 //
PR NEWSWIRE
Anixa Biosciences Transfers Breast Cancer Vaccine IND
15 Dec 2025 //
PR NEWSWIRE
Anixa Bio`s Phase 1 Breast Cancer Vaccine Meets Primary Endpoints
11 Dec 2025 //
PR NEWSWIRE
Anixa Bio Joins Water Tower Fireside Chat Dec. 15
10 Dec 2025 //
PR NEWSWIRE
Anixa Biosciences Secures WHO Approval for CAR-T Therapy
17 Nov 2025 //
PR NEWSWIRE
Anixa Biosciences Secures Key U.S. Patent for Breast Cancer
12 Nov 2025 //
PR NEWSWIRE
Anixa Bio Joins Water Tower Fireside Chat Nov. 11
10 Nov 2025 //
PR NEWSWIRE
Anixa Biosciences Signs Data Transfer Deal With Cleveland Clinic
05 Nov 2025 //
PR NEWSWIRE
Anixa Biosciences To Present At Spartan Capital Securities
23 Oct 2025 //
PR NEWSWIRE
Anixa Issues Chinese Patent For Breast Cancer Vaccine Technology
20 Oct 2025 //
PR NEWSWIRE
Anixa Biosciences Completes Final Visit In Breast Cancer Vaccine
07 Oct 2025 //
PR NEWSWIRE
Cleveland To Present Ph 1 Breast Cancer Vaccine Data for Anixa
22 Sep 2025 //
PR NEWSWIRE
Anixa Biosciences Reschedules H.C. Wainwright Conference
02 Sep 2025 //
PR NEWSWIRE
Anixa Biosciences to Present at H.C. Wainwright Global Conference
25 Aug 2025 //
PR NEWSWIRE
Anixa Biosciences Granted China Patent for Breast Cancer Vaccine
20 Aug 2025 //
PR NEWSWIRE
Anixa Biosciences Treats Second Patient in Ovarian Cancer
18 Aug 2025 //
PR NEWSWIRE
Dr Wenham to Discuss Ovarian Cancer Immunotherapy at Anixa Event
08 Aug 2025 //
PR NEWSWIRE
Anixa Begins US FDA IND Transfer for Ph 2 Breast Cancer Vaccine
04 Aug 2025 //
PR NEWSWIRE
Anixa Bio Gets US Patent for Breast Cancer Vaccine Until 2040
24 Jul 2025 //
PR NEWSWIRE
Anixa Biosciences Issues New U.S. Patent for Ovarian Cancer
09 Jul 2025 //
PR NEWSWIRE
Anixa Completes Enrollment In Ph1 Breast Cancer Vaccine Trial
02 Jun 2025 //
PR NEWSWIRE
Anixa Biosciences CEO Updates Shareholders on Progress & Milestone
19 May 2025 //
PR NEWSWIRE
Anixa Biosciences To Present At 18th European Life Sciences Forum
11 Feb 2025 //
PR NEWSWIRE
Anixa Biosciences Presents Ph 1 Breast Cancer Vaccine Data at SITC
08 Nov 2024 //
PR NEWSWIRE
Anixa Biosciences, Cleveland Clinic to Present Breast Cancer Data
28 Oct 2024 //
PR NEWSWIRE
Anixa Announces 2nd Dose Administered in Ovarian Cancer CAR-T Trial
15 Oct 2024 //
PR NEWSWIRE
Anixa Unveils Phase 2 Study Plan for Breast Cancer Vaccine
24 Sep 2024 //
PR NEWSWIRE
Anixa expands cancer vaccine collaboration with Cleveland Clinic
09 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology
27 Nov 2023 //
PR NEWSWIRE
Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board
21 Feb 2023 //
PR NEWSWIRE
